Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher ScientificGlobeNewsWire • 11/06/24
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024GlobeNewsWire • 10/31/24
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population Health, and Xenotransplantation at HUPO 2024GlobeNewsWire • 10/21/24
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewsWire • 08/22/24
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker DiscoveryGlobeNewsWire • 06/11/24
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ's Early Cancer Detection StudyGlobeNewsWire • 06/02/24
Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic SolutionsGlobeNewsWire • 05/08/24
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 OutlookGlobeNewsWire • 02/29/24
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker DiscoveryGlobeNewsWire • 02/06/24
Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom FisherZacks Investment Research • 02/02/24
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024GlobeNewsWire • 02/01/24
Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services ForumGlobeNewsWire • 11/10/23